Search results for "Musca"

showing 10 items of 300 documents

Non-neuronal acetylcholine involved in reproduction in mammals and honeybees.

2017

Bacteria and archaea synthesize acetylcholine (ACh). Thus, it can be postulated that ACh was created by nature roughly three billion years ago. Therefore, the wide expression of ACh in nature (i.e., in bacteria, archaea, unicellular organisms, plants, fungi, non-vertebrates and vertebrates and in the abundance of non-neuronal cells of mammals) is not surprising. The term non-neuronal ACh and non-neuronal cholinergic system have been introduced to describe the auto- and paracrine, that is, local regulatory actions of ACh in cells not innervated by neuronal cholinergic fibers and to communicate among themselves. In this way non-neuronal ACh binds to the nicotinic or muscarinic receptors expre…

0301 basic medicineMammalsInsecticidesNicotineCholinergic FibersBiologyBiochemistryEmbryonic stem cellReceptors MuscarinicAcetylcholineCell biology03 medical and health sciencesCellular and Molecular NeuroscienceParacrine signalling030104 developmental biologyNicotinic agonistCell MovementMuscarinic acetylcholine receptormedicineOviductAnimalsHumansAcetylcholineFunction (biology)medicine.drugJournal of neurochemistry
researchProduct

Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist/β2-Adrenoceptor Agonist Molecule with Long-Lasting Effect…

2019

AZD8871 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic obstructive pulmonary disease. This study describes the pharmacological profile of AZD8871 in in vitro and in vivo assays. AZD8871 is potent at the human M3 receptor (pIC50 in binding assays: 9.5) and shows kinetic selectivity for the M3 (half-life: 4.97 hours) over the M2 receptor (half-life: 0.46 hour). It is selective for the β2-adrenoceptor over the β1 and β3 subtypes (3- and 6-fold, respectively) and shows dual antimuscarinic and β2-adrenoceptor functional activity in isolated guinea pig tissue (pIC50 in electrically stimulated trachea: 8.6; pEC50 in spontaneous tone isolated trachea: 8.8, r…

0301 basic medicinePharmacologyAgonistChemistrymedicine.drug_classAntagonistMuscarinic antagonistMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2PropranololPharmacology03 medical and health sciences030104 developmental biology0302 clinical medicineIn vivoMuscarinic acetylcholine receptormedicineMolecular Medicine030217 neurology & neurosurgerymedicine.drugJournal of Pharmacology and Experimental Therapeutics
researchProduct

Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β 2 -adrenoceptor agonist (MA…

2017

LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases. This study investigated the pharmacological profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol. LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays). It is selective for the β2-adrenoceptor over the β1-and β3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compounds (pEC50 in spontaneous tone isolated trachea: 9.6). The relaxant potency of LAS190792 in electrically stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol sl…

0301 basic medicinePulmonary and Respiratory MedicineAgonistmedicine.drug_classBiochemistry (medical)OlodaterolAntagonistMuscarinic acetylcholine receptor M3Muscarinic antagonistPropranololPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicine030228 respiratory systemchemistryCompetitive antagonistMuscarinic acetylcholine receptormedicinePharmacology (medical)medicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Modulation of Hippocampal Circuits by Muscarinic and Nicotinic Receptors

2017

This article provides a review of the effects of activation of muscarinic and nicotinic receptors on the physiological properties of circuits in the hippocampal formation. Previous articles have described detailed computational hypotheses about the role of cholinergic neuromodulation in enhancing the dynamics for encoding in cortical structures and the role of reduced cholinergic modulation in allowing consolidation of previously encoded information. This article will focus on addressing the broad scope of different modulatory effects observed within hippocampal circuits, highlighting the heterogeneity of cholinergic modulation in terms of the physiological effects of activation of muscarin…

0301 basic medicinevolume transmissioncholinergic fibersCognitive NeuroscienceNeuroscience (miscellaneous)ReviewHippocampal formationReceptors NicotinicCholinergic modulationHippocampuslcsh:RC321-571tonic depolarization03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineNeuromodulationMuscarinic acetylcholine receptorNeural PathwaysmedicineAnimalsHumanslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryCholinergic FibersNicotinic ReceptorsChemistrypresynaptic inhibitionReceptors MuscarinicacetylcholineSensory Systems030104 developmental biologymedicine.anatomical_structureCholinergicNeuroscience030217 neurology & neurosurgeryAcetylcholinemedicine.drugNeuroscienceFrontiers in Neural Circuits
researchProduct

Effects of Long-Term Habitat Protection on Montane Small Mammals: Are Sorex araneus and S. minutus More Sensitive Than Previously Considered?

2022

Protection of natural areas by restricting human activities aims to preserve plant and animal populations and whole communities, ensuring the conservation of biological diversity and enhancement of ecosystem services. Therefore, it is expected that the longer the protection, the stronger the desired effects. We evaluated the responses of small mammals at the population and community levels under protection in the southern Carpathian Mountains. We surveyed small mammals for five years in sites with long- and short-term protection and non-protected. Besides protection status, we included elevation, habitat heterogeneity, and the month of survey as predictors in our models. As response variabl…

<i>S. minutus</i>habitat heterogeneityEcologyseasonalityQH301-705.5Ecological Modelingprotected areaBiology (General)Agricultural and Biological Sciences (miscellaneous)elevational patternprotected area; habitat heterogeneity; elevational pattern; seasonality; <i>Sorex araneus</i>; <i>S. minutus</i>; <i>Muscardinus avellanarius</i>; monitoring methods; conservation management; Southern Carpathians<i>Sorex araneus</i>Nature and Landscape ConservationDiversity
researchProduct

Modulation by Scopolamine, Acetylcholine and Choline of the Evoked Release of Acetylcholine from the Guinea Pig Myenteric Plexus: Evidence for a Musc…

1981

There is evidence that the release of acetylcholine (ACh) from the guinea pig myenteric plexus is controlled via presynaptic muscarine receptors. Muscarinic antagonists such as atropine enhance the release evoked by either electrical field stimulation, by nicotinic drugs or by high K+ concentrations (4,7,10). On the other hand, the muscarinic agonist oxotremorine inhibits the evoked release of ACh (7). A comparable feedback inhibition has been described for the release of ACh from central cholinergic nerves (for review, see Ref. 12). However, it has so far not been shown whether the physiological transmitter itself is able to depress the release of neuronal ACh. We have, therefore, studied …

Acetylcholine secretionChemistryAnesthesiaMuscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2Muscarinic acetylcholine receptor M1PharmacologyMuscarinic agonistMyenteric plexusAcetylcholinemedicine.drug
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Early management of COPD: Where are we now and where do we go from here? a delphi consensus project

2019

Fabiano Di Marco,1 Piero Balbo,2 Francesco de Blasio,3 Vittorio Cardaci,4 Nunzio Crimi,5 Giuseppe Girbino,6 Girolamo Pelaia,7 Pietro Pirina,8 Pietro Roversi,9 Pierachille Santus,10,11 Nicola Scichilone,12 Alessandro Vatrella,13 Patrizio Pasqualetti,14 Mauro Carone15 1Department of Health Sciences, University of Milan, Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2SC Malattie dell&amp;rsquo;Apparato Respiratorio, AOU Maggiore della Carit&amp;agrave;, Novara, Italy; 3Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center S.p.A. Private Hospital, Department of Medicine and Health Sciences &amp;ldquo;V Tiberio&amp;rdquo;, University of Molise, Campobasso, It…

Adrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinedrug combinationspractice guidelines as topicConsensuPredictive Value of Testbronchodilator therapy; dyspnea; italy; respiratory symptoms; adrenal cortex hormones; adrenergic beta-2 receptor agonists; adult; bronchodilator agents; consensus; delphi technique; drug combinations; early diagnosis; early medical intervention; evidence-based medicine; female; humans; italy; male; middle aged; muscarinic antagonists; practice guidelines as topic; predictive value of tests; pulmonary disease; chronic obstructive; surveys and questionnaires; treatment outcomeadrenal cortex hormonesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseasedyspnoeaAdrenal Cortex HormonePulmonary Disease Chronic ObstructivemaleDrug CombinationEarly Diagnosiitalymiddle agedSurveys and Questionnairehumansmuscarinic antagonistsBronchodilator AgentOriginal Researchearly medical interventionpulmonary diseaselcsh:RC705-779chronic obstructiveHealth Policyadultbronchodilator agentsEnvironmental and Occupational Healthrespiratory symptomsbronchodilator therapylcsh:Diseases of the respiratory systemdyspneaBronchodilator therapy; Dyspnea; Italy; Respiratory symptoms; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational Healthpredictive value of testsMuscarinic AntagonistfemaleconsensusRespiratory symptomsurveys and questionnairestreatment outcomePublic Healthdelphi techniqueadrenergic beta-2 receptor agonistsevidence-based medicineHumanearly diagnosis
researchProduct

Nonlinear coupling is absent in acute myocardial patients but not healthy subjects.

2008

We investigated whether autonomic nervous system imbalance imposed by pharmacological blockades and associated with acute myocardial infarction (AMI) is manifested as modifications of the nonlinear interactions in heart rate variability signal using a statistically based bispectrum method. The statistically based bispectrum method is an ideal approach for identifying nonlinear couplings in a system and overcomes the previous limitation of determining in an ad hoc way the presence of such interactions. Using the improved bispectrum method, we found significant nonlinear interactions in healthy young subjects, which were abolished by the administration of atropine but were still present afte…

AdultAtropineMaleSympathetic Nervous SystemPhysiologyAdrenergic beta-AntagonistsModels NeurologicalMyocardial InfarctionMuscarinic AntagonistsElectrocardiographyHeart RateParasympathetic Nervous SystemPhysiology (medical)medicineAutonomic nervous systemHumansMyocardial infarctionNonlinear couplingHeart rate variabilityAgedBispectrumModels Statisticalbusiness.industryHealthy subjectsAge FactorsModels CardiovascularReproducibility of ResultsHeartMiddle Agedmedicine.diseasePropranololAutonomic nervous systemNonlinear DynamicsAnesthesiaCase-Control StudiesSettore ING-INF/06 - Bioingegneria Elettronica E InformaticaFemalebusinessCardiology and Cardiovascular MedicineAlgorithmsAmerican journal of physiology. Heart and circulatory physiology
researchProduct

Cardiovascular control and time domain granger causality: Insights from selective autonomic blockade

2013

We studied causal relations among heart period (HP), systolic arterial pressure (SAP) and respiration (R) according to the definition of Granger causality in the time domain. Autonomic pharmacological challenges were used to alter the complexity of cardiovascular control. Atropine (AT), propranolol and clonidine (CL) were administered to block muscarinic receptors, β-adrenergic receptors and centrally sympathetic outflow, respectively. We found that: (i) at baseline, HP and SAP interacted in a closed loop with a dominant causal direction from HP to SAP; (ii) pharmacological blockades did not alter the bidirectional closed-loop interactions between HP and SAP, but AT reduced the dominance of…

AdultMaleGeneral MathematicsGeneral Physics and AstronomyBlood PressurePropranololPharmacologyBaroreflexArterial pressure variability; Autonomic nervous system; Baroreflex; Cardiovascular control; Granger causality; Heart rate variability; Mathematics (all); Engineering (all); Physics and Astronomy (all)Models BiologicalPhysics and Astronomy (all)Engineering (all)Respiratory RateGranger causalityBiological ClocksHeart RateMuscarinic acetylcholine receptormedicineHumansHeart rate variabilityAutonomic nervous systemMathematics (all)Computer SimulationHeart rate variabilityFeedback PhysiologicalChemistryGeneral EngineeringMiddle AgedBaroreflexClonidineAtropineAutonomic nervous systemCardiovascular controlSettore ING-INF/06 - Bioingegneria Elettronica E InformaticaGranger causalityFemaleArterial pressure variabilityAutonomic Nerve Blockmedicine.drug
researchProduct